Basic Information
RNALocate ID: | RLID:11001483 |
RNA Symbol: | hsa-miR-205-5p |
Localization: | Microvesicle |
RNA Information
RNA Name: | hsa-miR-205 |
RNA ID: | miRBase:MIMAT0000266 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 20615901 |
Tissue/Cell Line: | Hepatocellular carcinoma cell line (HepG2)|Lung epithelial carcinoma cell line (A549) |
Method: | Microarray|RT-PCR |
Originally published in Nucleic Acids Res. Wang K, et al, 2010. Reproduced under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) |
|
Description: | These observations of miRNA distribution demonstrate that the miRNA export system in the cells must somehow be able to target specific miRNAs to specific extracellular structures, but does not exclusively channel specific miRNAs to a given fraction. There are, however, some miRNAs that are found in the supernatant almost to the exclusion of all other fractions (miR-219 in A549 culture medium, Figure 4b, for example). Another significant observation from this data is that even though we showed that the two cell lines studied here export a similar spectrum of miRNAs (Figure 1b) the distributions of miRNAs from the two cell lines demonstrate clear differences, as shown in Figure 4b and c. For example, miR-145 is present at very low levels in HepG2 derived microvesicles (Figure 4c), while the same miRNA is present at significant levels in both A549 derived microvesicles and exosomes (Figure 4b). On the other hand, there are some miRNAs, notably those that are almost uniformly distributed among the fractions, with the same distribution no matter which cell-line is the source. These observations certainly indicate the degree of complexity of this export system that will bear further investigation. Data are collected from Figure 4. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001645 | Cytoplasm | Tumor tissues (Head|Neck) | 25422181 |
RLID:01001646 | Nucleus | Tumor tissues (Head|Neck) | 25422181 |
RLID:11001475 | Exosome | Urine | 26576778 |
RLID:11001476 | Exosome | Primary ovarian tumor cells|Serum | 18589210 |
RLID:11001477 | Exosome | Plasma | 19289371 |
RLID:11001478 | Exosome | Hepatocellular carcinoma cell line (HepG2)|Lung epithelial carcinoma cell line (A549) | 20615901 |
RLID:11001479 | Exosome | Ascites fluid|Pleural effusion | 21601258 |
RLID:11001480 | Exosome | Breast milk | 22211110 |
RLID:11001481 | Exosome | Brain tissue | 23382797 |
RLID:11001482 | Exosome | Plasma | 23663360 |
RLID:11001484 | Microvesicle | Seminal plasma | 23539611 |
RLID-D:11000057 | Exosome | Breast milk|Tongue tissue | |
RLID-D:11000327 | Microvesicle | Mesenchymal stem cells|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-205-5p | Splenic marginal zone lymphoma | MNDR-E-MI-27139 |
MNDR | hsa-miR-205-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-27140 |
MNDR | hsa-miR-205-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-27141 |
MNDR | hsa-miR-205-5p | Lymphoma | MNDR-E-MI-27142 |
MNDR | hsa-miR-205-5p | Lymphoma non-hodgkin | MNDR-E-MI-27143 |
MNDR | hsa-miR-205-5p | Cutaneous t cell lymphoma | MNDR-E-MI-27144 |
MNDR | hsa-miR-205-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-27145 |
MNDR | hsa-miR-205-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-27146 |
MNDR | hsa-miR-205-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-27147 |
MNDR | hsa-miR-205-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-27148 |
MNDR | hsa-miR-205-5p | Her2-receptor positive breast cancer | MNDR-E-MI-27149 |
MNDR | hsa-miR-205-5p | Triple negative breast cancer | MNDR-E-MI-27150 |
MNDR | hsa-miR-205-5p | Prostate cancer | MNDR-E-MI-27151 |
MNDR | hsa-miR-205-5p | Prostate carcinoma | MNDR-E-MI-27152 |
MNDR | hsa-miR-205-5p | Gastric cancer | MNDR-E-MI-27153 |
MNDR | hsa-miR-205-5p | Gastric lymphoma | MNDR-E-MI-27154 |
MNDR | hsa-miR-205-5p | Alzheimer disease | MNDR-E-MI-27155 |
MNDR | hsa-miR-205-5p | Bladder cancer | MNDR-E-MI-27156 |
MNDR | hsa-miR-205-5p | Esophageal carcinoma | MNDR-E-MI-27157 |
MNDR | hsa-miR-205-5p | Head and neck cancer | MNDR-E-MI-27158 |
MNDR | hsa-miR-205-5p | Hereditary hemorrhagic telangiectasia | MNDR-E-MI-27159 |
MNDR | hsa-miR-205-5p | Ataxia telangiectasia | MNDR-E-MI-27160 |
MNDR | hsa-miR-205-5p | Huntington disease | MNDR-E-MI-27161 |
MNDR | hsa-miR-205-5p | Cardiovascular disease | MNDR-E-MI-27162 |
MNDR | hsa-miR-205-5p | Lung cancer | MNDR-E-MI-27163 |
MNDR | hsa-miR-205-5p | Endometrial cancer | MNDR-E-MI-27164 |
MNDR | hsa-miR-205-5p | Parkinson disease | MNDR-E-MI-27165 |
MNDR | hsa-miR-205-5p | Machado-joseph disease | MNDR-E-MI-27166 |
MNDR | hsa-miR-205-5p | Breast cancer | MNDR-E-MI-27167 |
MNDR | hsa-miR-205-5p | Aggressive squamous cell carcinoma | MNDR-E-MI-27168 |
MNDR | hsa-miR-205-5p | Thyroid cancer | MNDR-E-MI-27169 |
MNDR | hsa-miR-205-5p | Pituitary neoplasms | MNDR-E-MI-27170 |
MNDR | hsa-miR-205-5p | Malignant mesothelioma | MNDR-E-MI-27171 |
MNDR | hsa-miR-205-5p | Pancreatic cancer | MNDR-E-MI-27172 |
MNDR | hsa-miR-205-5p | Melanoma | MNDR-E-MI-27173 |
MNDR | hsa-miR-205-5p | Colon cancer | MNDR-E-MI-27174 |
MNDR | hsa-miR-205-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-27175 |
MNDR | hsa-miR-205-5p | Ovarian cancer | MNDR-E-MI-27176 |
MNDR | hsa-miR-205-5p | Prostate adenocarcinoma | MNDR-E-MI-27177 |
MNDR | hsa-miR-205-5p | Renal cancer | MNDR-E-MI-27178 |
MNDR | hsa-miR-205-5p | Endometrial carcinoma | MNDR-E-MI-27179 |
MNDR | hsa-miR-205-5p | Carcinoma ductal breast | MNDR-E-MI-27180 |
MNDR | hsa-miR-205-5p | Balkan nephropathy | MNDR-E-MI-27181 |
MNDR | hsa-miR-205-5p | Glioblastoma | MNDR-E-MI-27182 |
MNDR | hsa-miR-205-5p | Glioma | MNDR-E-MI-27183 |
MNDR | hsa-miR-205-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-27184 |
MNDR | hsa-miR-205-5p | Osteosarcoma | MNDR-E-MI-27185 |
MNDR | hsa-miR-205-5p | Breast carcinoma | MNDR-E-MI-27186 |
MNDR | hsa-miR-205-5p | Uterine cancer | MNDR-E-MI-27187 |
MNDR | hsa-miR-205-5p | Cervical adenocarcinoma | MNDR-E-MI-27188 |
MNDR | hsa-miR-205-5p | Gastric adenocarcinoma | MNDR-E-MI-27189 |
MNDR | hsa-miR-205-5p | Cervical squamous cell carcinoma | MNDR-E-MI-27190 |
MNDR | hsa-miR-205-5p | Pituitary adenoma | MNDR-E-MI-27191 |
MNDR | hsa-miR-205-5p | Lung squamous cell carcinoma | MNDR-E-MI-27192 |
MNDR | hsa-miR-205-5p | Carcinoma lung non-small-cell | MNDR-E-MI-27193 |
MNDR | hsa-miR-205-5p | Lung adenocarcinoma | MNDR-E-MI-27194 |
MNDR | hsa-miR-205-5p | Thyroid carcinoma | MNDR-E-MI-27195 |
MNDR | hsa-miR-205-5p | Ovarian carcinoma | MNDR-E-MI-27196 |
MNDR | hsa-miR-205-5p | Bladder urothelial carcinoma | MNDR-E-MI-27197 |
MNDR | hsa-miR-205-5p | Pancreatic adenocarcinoma | MNDR-E-MI-27198 |
MNDR | hsa-miR-205-5p | Cervical cancer | MNDR-E-MI-27199 |
MNDR | hsa-miR-205-5p | Biliary tract cancer | MNDR-E-MI-27200 |
MNDR | hsa-miR-205-5p | Esophageal cancer | MNDR-E-MI-27201 |
MNDR | hsa-miR-205-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-27202 |
MNDR | hsa-miR-205-5p | Breast invasive carcinoma | MNDR-E-MI-27203 |
MNDR | hsa-miR-205-5p | Hepatocellular carcinoma | MNDR-E-MI-27204 |
MNDR | hsa-miR-205-5p | B-cell lymphoma | MNDR-E-MI-27205 |
MNDR | hsa-miR-205-5p | Rheumatoid arthritis | MNDR-E-MI-27206 |
MNDR | hsa-miR-205-5p | T-cell leukemia | MNDR-E-MI-27207 |
MNDR | hsa-miR-205-5p | Neuroblastoma | MNDR-E-MI-27208 |
MNDR | hsa-miR-205-5p | Barrett's adenocarcinoma | MNDR-E-MI-27209 |
MNDR | hsa-miR-205-5p | Influenza | MNDR-E-MI-27210 |
MNDR | hsa-miR-205-5p | Burkitt lymphoma | MNDR-E-MI-27211 |
MNDR | hsa-miR-205-5p | Kb oral cancer | MNDR-E-MI-27212 |
MNDR | hsa-miR-205-5p | Skin cutaneous melanoma | MNDR-E-MI-27213 |
MNDR | hsa-miR-205-5p | Skin melanoma | MNDR-E-MI-27214 |
MNDR | hsa-miR-205-5p | Colorectal cancer | MNDR-E-MI-27215 |
MNDR | hsa-miR-205-5p | Nasopharyngeal carcinoma | MNDR-E-MI-27216 |
MNDR | hsa-miR-205-5p | Nasopharynx carcinoma | MNDR-E-MI-27217 |
MNDR | hsa-miR-205-5p | Multiple myeloma | MNDR-E-MI-27218 |
MNDR | hsa-miR-205-5p | Ovarian epithelial cancer | MNDR-E-MI-27219 |
MNDR | hsa-miR-205-5p | Esophageal squamous cell carcinoma | MNDR-E-MI-27220 |
MNDR | hsa-miR-205-5p | Uterine cervical neoplasms | MNDR-E-MI-27221 |
MNDR | hsa-miR-205-5p | Nasopharyngeal cancer | MNDR-E-MI-27222 |
MNDR | hsa-miR-205-5p | Cerebral hemorrhage traumatic | MNDR-E-MI-27223 |
MNDR | hsa-miR-205-5p | Intracranial hemorrhage hypertensive | MNDR-E-MI-27224 |
MNDR | hsa-miR-205-5p | Barrett's carcinogenesis | MNDR-E-MI-27225 |
MNDR | hsa-miR-205-5p | Breast cancer her3+ negative | MNDR-E-MI-27226 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ABCC2 | Homo sapiens | RR00023539 |
TOP